罗沙司他在慢性肾脏病患者肾性贫血治疗中的效果评价

Evaluation of the Effect of Roxadustat in the Treatment of Renal Anemia in Patients with Chronic Kidney Disease

目的探讨在慢性肾脏病患者肾性贫血治疗中采用罗沙司他的效果。方法选择2022年1月—2023年1月连云港市第二人民医院收治的慢性肾脏病合肾性贫血患者80例,按随机数表法分为对照组(40例,重组人促红素治疗)与研究组(40例,罗沙司他治疗),比较两组治疗前后贫血指标、铁代谢指标、血脂代谢指标及不良反应情况。结果与治疗前相比,治疗后两组Hb、Hct、RBC水平均升高,且研究组Hb、Hct、RBC水平为(117.35±9.62)g/L、(38.07±3.51)%、(3.04±0.56)×10^(12)/L,均高于对照组的(106.42±8.46)g/L、(30.63±3.16)%、(2.36±0.47)×10^(12)/L,差异有统计学意义(t=5.396、9.963、5.883,P<0.05)。与治疗前相比,两组治疗后TRF、SF、TSAT水平均升高,Hepc水平则下降,且研究组改善幅度高于对照组,差异有统计学意义(P<0.05)。与治疗前相比,两组治疗后TCH、LDL水平均下降,且研究组TCH、LDL水平均低于对照组,差异有统计学意义(P<0.05)。与对照组相比,研究组不良反应发生率更低,差异有统计学意义(P<0.05)。结论在慢性肾脏病合并肾性贫血患者治疗中采用罗沙司他的效果理想,能够改善机体贫血状态,并调节机体铁代谢与血脂代谢水平,且不良反应少,值得推广。

Objective To investigate the effect of using roxadustat in the treatment of renal anemia in patients with chronic kidney disease.Methods Eighty patients with chronic kidney disease combined with renal anemia admitted to the Second People's Hospital of Lianyungang City from January 2022 to January 2023 were divided into control group(40 cases treated with recombinant human erythropoietin)and study group(40 cases treated with rosalrestat)according to random number table method.Anemia indexes,iron metabolism indexes,lipid metabolism indexes before and after treatment and adverse reactions of the two groups were compared.Results Compared with before treatment,the Hb,Hct and RBC levels in both groups increased after treatment,and the Hb,Hct and RBC levels in the study group were(117.35±9.62)g/L,(38.07±3.51)%,(3.04±0.56)×10^(12)/L,respectively,which were higher than those in the control group(106.42±8.46)g/L,(30.63±3.16)%,(2.36±0.47)×10^(12)/L,the difference was statistically significant(t=5.396,9.963,5.883,P<0.05).Compared with before treatment,TRF,SF and TSAT levels increased in both groups after treatment,while Hepc levels decreased,and the improvement was higher in the study group than in the control group,the difference was statistically significant(P<0.05).Compared with before treatment,TCH and LDL levels decreased in both groups after treatment,and TCH and LDL levels in the study group were lower than those in the control group,the difference was statistically significant(P<0.05).Adverse reaction rate were lower in the study group compared with those in the control group,the difference was statistically significant(P<0.05).Conclusion The use of roxadustat in the treatment of patients with chronic kidney disease combined with renal anemia is ideal,can improve the body's ane-mia status and regulate the body´s iron metabolism and lipid metabolism levels,and less adverse reactions,and is worth promoting.